JAMP MIDODRINE TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
30-06-2021
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MIDODRINE HYDROCHLORIDE
Fáanlegur frá:
JAMP PHARMA CORPORATION
ATC númer:
C01CA17
INN (Alþjóðlegt nafn):
MIDODRINE
Skammtar:
5MG
Lyfjaform:
TABLET
Samsetning:
MIDODRINE HYDROCHLORIDE 5MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
15G/50G
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ALPHA-ADRENERGIC AGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0123066002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2021-07-08
Vara einkenni
Page 1 of 22
PRODUCT MONOGRAPH
Pr
JAMP MIDODRINE
Midodrine Hydrochloride Tablets USP
2.5 mg and 5 mg of midodrine hydrochloride
Vasopressor
JAMP PHARMA CORPORATION
1310 rue Nobel
Boucherville, Qu
é
bec
J4B 5H3
DATE OF PREPARATION:
June 30, 2021
CONTROL NO.: 235448
Page 2 of 22
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 4
SUMMARY PRODUCT INFORMATION
.........................................................................
4
INDICATIONS AND CLINICAL USE
..............................................................................
4
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
..................................................................................
5
ADVERSE
REACTIONS...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................10
OVERDOSAGE
...............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
...............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................13
PART II: SCIENTIFIC
INFORMATION.........................................................................
14
PHARMACEUTICAL INFORMATION
...........................................................................14
CLINICAL TRIALS
.........................................................................................................16
DETAILED PHARMACOLOGY
............................................................................
Lestu allt skjalið
